10亿美元收购后，阿斯利康体内CAR-T疗法首战告捷

药事纵横07-09

阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后，7月7日，其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据，为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示，ESO-T01在单次静脉输注后即展现积极疗效：2例达到严格完全缓解（sCR），2例获得部分缓解（PR）。值得关注的是，受试患者均为经...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550687533?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-09 17:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550687533","market":"us","top_or_hot":-1,"title":"10亿美元收购后，阿斯利康体内CAR-T疗法首战告捷","media":"药事纵横","content":"<div>\n<p>阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后，7月7日，其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据，为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示，ESO-T01在单次静脉输注后即展现积极疗效：2例达到严格完全缓解（sCR），2例获得部分缓解（PR）。值得关注的是，受试患者均为经...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10亿美元收购后，阿斯利康体内CAR-T疗法首战告捷</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10亿美元收购后，阿斯利康体内CAR-T疗法首战告捷\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-09 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b><strong>药事纵横</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后，7月7日，其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据，为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示，ESO-T01在单次静脉输注后即展现积极疗效：2例达到严格完全缓解（sCR），2例获得部分缓解（PR）。值得关注的是，受试患者均为经...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b","article_id":"2550687533","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550687533","pubTimestamp":1752051600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后，7月7日，其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据，为这家传统药企的细胞基因治疗布局注入强心剂。此次收购是阿斯利康深化细胞基因治疗布局的关键一步。随着首个临床数据的公布，这款颠覆性体内CAR-T疗法的后续开发进程，将成为检验传统药企转型创新生物技术领域成效的重要标尺。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","CAR":"安飞士","BK4230":"旅客陆运","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AZN":"阿斯利康","BK4022":"陆运","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"After $1 billion acquisition, AstraZeneca's in vivo CAR-T therapy won its first battle","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"CAR":1},"content_text":"阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后，7月7日，其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据，为这家传统药企的细胞基因治疗布局注入强心剂。这项针对中国4例难治性多发性骨髓瘤患者的Ⅰ期试验结果显示，ESO-T01在单次静脉输注后即展现积极疗效：2例达到严格完全缓解（sCR），2例获得部分缓解（PR）。值得关注的是，受试患者均为经多线治疗失败的极端案例——包括五重耐药且广泛髓外转移、干细胞移植后复发、四线治疗耐药伴大面积髓外病灶，以及既往BCMA靶向CAR-T治疗失败的患者。与传统CAR-T疗法需体外提取、改造、回输T细胞的复杂流程不同，ESO-T01采用创新性的\"体内编程\"策略：通过纳米抗体靶向的慢病毒载体，直接在患者体内将T细胞重编程为CAR-T细胞。这种设计旨在规避传统疗法\"制造周期长、成本高昂、患者等待时间长\"的痛点。研究团队推测，更小的病毒颗粒尺寸或提升了肿瘤组织渗透能力，同时体内生成的CAR-T细胞可能具备更优的肿瘤归巢能力及肿瘤微环境适应性。具体疗效方面，首例五重耐药患者在治疗第二个月实现骨髓及髓外病灶完全消退；第二例患者在28天内达成完全缓解；后两例部分缓解患者则出现肿瘤负荷缩小及骨髓微小残留病灶转阴。安全性方面，所有患者仅出现1级细胞因子释放综合征（CRS），1例高肿瘤负荷患者发生1级神经毒性综合征（ICANS），均通过糖皮质激素有效控制。血液学毒性以3-4级中性粒细胞减少为主，多数在随访期缓解；2例患者出现肺部感染，经抗生素治疗后康复。此次收购是阿斯利康深化细胞基因治疗布局的关键一步。公司以4.25亿美元首付加5.75亿美元里程碑付款拿下ESO-T01权益，延续了其近年在该领域的一系列动作，此前已通过投资Gracell、Neogene Therapeutics等企业构建技术护城河。随着首个临床数据的公布，这款颠覆性体内CAR-T疗法的后续开发进程，将成为检验传统药企转型创新生物技术领域成效的重要标尺。药事纵横投稿须知：稿费已上调，欢迎投稿","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550687533","isCrawlerRequest":true}